1 / 54

Comment gérer un traitement anticoagulant au quotidien

Comment gérer un traitement anticoagulant au quotidien. Stephane EDERHY Service de cardiologie Hôpital SAINT ANTOINE. Fibrillation Atriale. Quel risque ?. Cardiovascular morbidity and mortality associated with Atrial Fibrillation. Kirchoff ESC Guidelines 2016.

turi
Download Presentation

Comment gérer un traitement anticoagulant au quotidien

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comment gérer un traitement anticoagulant au quotidien Stephane EDERHY Service de cardiologie Hôpital SAINT ANTOINE

  2. Fibrillation Atriale Quel risque ?

  3. Cardiovascularmorbidity and mortalityassociatedwith Atrial Fibrillation Kirchoff ESC Guidelines 2016

  4. Conditions associatedwith AF Kirchoff ESC Guidelines 2016

  5. Fibrillation Atriale Comment évaluer le risque thromboembolique ?

  6. Clinicalriskfactors for stroke, TIA and systemicembolism Kirchoff ESC Guidelines 2016

  7. Fibrillation Atriale Comment évaluer le risque hémorragique ?

  8. Modifiable and non-modifiable riskfactors for bleeding in anticoagulated patients based on bleedingrisk scores

  9. Fibrillation Atriale Quel traitement ?

  10. Stroke prevention in Atrial Fibrillation Kirchoff ESC Guidelines 2016

  11. Fibrillation Atriale Comment prescrire ? Interactions médicamenteuses Fonction rénale

  12. P-GP / CYP Drug-Drug Interactions Gastro intestinal tract CYP3A4 P-gp P-gp CYP2J BCRP CYP3A4 P-gp bile Renal Tubular Cells Enterocyte Hepatocyte

  13. Absorption

  14. P-Gp / CYP

  15. List of substrates,inhibitors and inducers of CYP3A4 and P-glycoprotein Heidbuchel Europace 2013 ;15:625-651

  16. Effect on NOAC plasma levels from drug-drug intercations

  17. Fibrillation Atriale Anticoagulant et Fonction renale

  18. Dose adjustment for NOACs as evaluated in the PHASE III trials Kirchoff ESC Guidelines 2016

  19. Adaptation de dose et fonction rénale

  20. Risque thrombo embolique et Adaptation de dose et fonction rénale

  21. Risuqehemorragique et Adaptation de dose et fonction rénale

  22. AF and CKD stage IIIstroke

  23. AF and CKD stage IIIbleeding

  24. Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction Yao J Am CollCardiol 2017;69:2779–90

  25. Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction Yao J Am CollCardiol 2017;69:2779–90

  26. Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction OVERDOSING UNDERDOSING Yao J Am CollCardiol 2017;69:2779–90

  27. Fibrillation Atriale Anticoagulant et Valvulopathie

  28. Non–Vitamin K AntagonistOral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Renda J Am CollCardiol 2017 ; 69 : 1363 - 71

  29. Fibrillation Atriale Relais ?

  30. Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Low hemorrhagic risk procedureUpdated guidelines from the French Working Group on Perioperative Hemostasis Albaladejo P AnaesthCritCare Pain Med 2017 ;36 : 73–76

  31. NVAF patients with and acute TIA or ischaemic stroke

  32. Atrial Fibrillation Hémorragie active

  33. NVAF patient withintracranialbleed on OAC

  34. NVAF Patients with active bleeding

  35. Fibrillation Atriale Maladie coronaire

  36. NVAF patient in need of OAC after ACS

  37. NVAF patient in need of OAC afterelective PCI withstent

  38. European Heart Rhythm association proposal for a universal NOAC anticoagulation card

  39. European Heart Rhythm association proposal for a universal NOAC anticoagulation card

  40. Practical SuggestionsMonitoring 1- Stratification du risque 2- Interaction medicamenteuse 3- Fonction rénale 4- Education thérapeutique

  41. Back UP

  42. List of substrates,inhibitors and inducers of CYP3A4 and P-glycoprotein Heidbuchel Europace 2013 ;15:625-651

  43. RivaroxabanP-gp/CYP Gong Can J Cardiol 2013 ;29:S24

  44. Apixaban Gong Can J Cardiol 2013 ;29:S24

  45. eCrCL estimated based on Cockroft-Gault equation Exclusion criteriarelated to CKD Dose Adjustmentrelated to CKD

  46. DabigatranCKD

More Related